ASCO 2019: Promising new data for patients with relapsed/refractory follicular lymphoma

Catherine S. Diefenbach | | Juni 6, 2019

Föreläsare: Catherine S. Diefenbach

In this MEDtalk Catherine Diefenbach presents a pre-planned interim analysis of the safety/efficacy of induction and maintenance with Polatuzumab vedotin (Pola) + obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma.